Physician profile
Jonathan D Altus
NPI 1871575647
$8,820.62
in general payments reported to CMS, 2019-2025
32 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $812 · 2021: $1,207 · 2022: $1,158 · 2023: $1,244 · 2024: $1,334 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,393.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,073.05 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,122.91 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,248.40 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Genzyme Corporation | $504.47 | 2019-2025 | |
| Mylan Specialty L.P. | $345.38 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $213.59 | 2024-2025 | Dupixent |
| Baxter Healthcare | $162.86 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $136.05 | 2025 | Ohtuvayre |
| Amgen INC. | $135.25 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $93.83 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $61.62 | 2022 | |
| Shionogi INC | $60.94 | 2022-2024 | Fetroja |
| Olympus America INC. | $60.70 | 2019 | |
| Inspire Medical Systems, INC. | $58.34 | 2025 | Inspire |
| Advanced Respiratory, INC | $54.62 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $48.83 | 2022 | |
| Grifols USA, LLC | $44.05 | 2019 | |
| Gilead Sciences, INC. | $43.40 | 2021-2022 | |
| Philips North America LLC | $39.28 | 2020-2021 | |
| Viatris Specialty LLC | $38.68 | 2025 | Yupelri |
| Covidien LP | $37.14 | 2019 | |
| Circassia INC. | $32.56 | 2019 | |
| Ceribell, INC. | $30.26 | 2024 | Pocket Eeg Device |
| Abbvie INC. | $27.08 | 2023 | Teflaro |
| Lilly USA, LLC | $26.28 | 2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $21.72 | 2021 | |
| Insmed, INC. | $21.33 | 2025 | Arikayce |
| Electromed, INC. | $20.60 | 2021 | |
| United Therapeutics Corporation | $17.90 | 2021 | |
| Chiesi USA, INC. | $15.77 | 2020 | |
| Merck Sharp & Dohme LLC | $12.35 | 2019 | |
| Inari Medical, INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Altus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.